Developing Regenerative Medicine for Ischemic Heart Failure

Cardia Therapeutics is a regenerative medicine company and a CytoHub company focused on developing HeartReady, a cellular therapy for ischemic heart failure.
Cardia Therapeutics

Our Focus

Ischemic heart failure affects millions of patients worldwide and results from permanent damage to heart tissue caused by reduced blood flow. Despite advances in medical care, many patients experience progressive loss of cardiac function and limited treatment options.

HeartReady

HeartReady is a cellular therapy being developed specifically for ischemic heart failure. The therapy is designed to promote repair and recovery of heart tissue following ischemic injury, with the goal of improving cardiac function and patient outcomes.

How We Operate

Cardia Therapeutics operates as a subsidiary of CytoHub with independent management and development responsibility for HeartReady. As a CytoHub company, Cardia Therapeutics may access platform capabilities through CytoHub’s CardioVive and Bioengine businesses on a commercial basis.

Looking Ahead

Cardia Therapeutics is advancing HeartReady toward clinical development with the goal of delivering a regenerative therapy that addresses the underlying tissue damage associated with ischemic heart failure.